trending Market Intelligence /marketintelligence/en/news-insights/trending/1UM2_P04P8x2b-uNQ0D1Fw2 content esgSubNav
In This List

Dechra completes acquisition of Brazilian animal health company Venco

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Dechra completes acquisition of Brazilian animal health company Venco

Dechra Pharmaceuticals PLC completed its acquisition of Laboratórios Vencofarma do Brasil Ltda., a Brazilian animal health company, for 185 million reais.

Laboratórios Vencofarma Do Brasil, or Venco, sells vaccines and products for food-producing animals, mainly in Brazil. The company, which also sells companion animal products, is based in Londrina City in Brazil's Paraná state.

Dechra used existing cash and borrowing facilities to finance the deal.

The acquisition provides U.K.-based Dechra with a strategic presence within the Brazilian and South American markets. Dechra said it plans to invest significantly over the next two to three years to develop its business in South America.

Dechra develops and sells animal medicines and related products globally. In January, the company raised £105 million to fund similar deals in the Netherlands.

As of Dec. 17, US$1 was equivalent to 3.89 Brazilian reais.